← Back to Search

Prodrug

TF0023 for Coronavirus Pneumonia

Phase 2
Waitlist Available
Research Sponsored by Techfields Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 days
Awards & highlights

Study Summary

This trial is testing a new drug to see if it can help relieve symptoms of ARDS and pneumonia caused by COVID-19.

Eligible Conditions
  • Coronavirus Pneumonia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of patients able to maintain peripheral capillary oxygen saturation (SpO2) of >93% without oxygen support at Day 15.
Secondary outcome measures
All-cause mortality
Changes of chest x-ray, and computerized tomography (CT) scan
Changes of clinical status (9-point ordinal scale)
+7 more

Trial Design

4Treatment groups
Experimental Treatment
Group I: Low Dose of Active DrugExperimental Treatment1 Intervention
80 patients will be randomly assigned to low dose, take active drug BID.
Group II: Low Dose Placebo ControlExperimental Treatment1 Intervention
80 patients will be randomly assigned to Low dose placebo, take the placebo BID.
Group III: High Dose of Active DrugExperimental Treatment1 Intervention
160 patients will be randomly assigned to high dose, take the active drug BID.
Group IV: High Dose Placebo ControlExperimental Treatment1 Intervention
80 will be randomly assigned to high dose placebo, take the placebo BID.

Find a Location

Who is running the clinical trial?

Techfields IncLead Sponsor
1 Previous Clinical Trials
225 Total Patients Enrolled
Chongxi Yu, Ph.DStudy ChairTechfields Inc
1 Previous Clinical Trials
225 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the cap on participants in this medical study?

"Affirmative. According to the information on clinicaltrials.gov, this research endeavour is actively accepting participants and was initially posted on May 10th 2022 with a subsequent update on May 24th 2022. The team behind this trial seeks 400 subjects from 2 medical facilities."

Answered by AI

Are there still openings for participants in this research trial?

"Clinicaltrials.gov discloses that this medical experiment, which was originally advertised on May 10th 2022, is actively recruiting patients. It has undergone a recent update as of May 24th 2022."

Answered by AI

To what extent does TF0023 pose a hazard to individuals?

"Due to the fact that TF0023 is in Phase 2 of its clinical trial, our team at Power has rated this drug's safety as a score of 2. This signifies that there some data supporting its security, but none attesting to its efficacy yet."

Answered by AI

Who else is applying?

What state do they live in?
Virginia
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
Evaluate the Efficacy and Safety of TF0023 in Treatments for COVID-19 in Hospitalized Adults
2022. "Evaluate the Efficacy and Safety of TF0023 in Treatments for COVID-19 in Hospitalized Adults". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05212818.
~7 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top